Reported its financial results for the three-month period ended June 30, 2022. Unless otherwise noted, ...
TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its...
Has entered into an amending agreement with First Generation Capital Inc., a company affiliated with ...
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it...
TORONTO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and...
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from...
Has entered into an amending agreement with First Generation Capital Inc., a company affiliated with ...
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it...
TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCD) today announced that it...